Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)
Previous Close
$21.09
52W Range
$15.52 - $28.15
50D Avg
$24.29
200D Avg
$21.84
Market Cap
$1.54B
Avg Vol (3M)
$363.41K
Beta
0.35
Div Yield
-
KNSA Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
NUVL | Nuvalent, Inc. |
GOSS | Gossamer Bio, Inc. |
CGEM | Cullinan Oncology, Inc. |
LRMR | Larimar Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
PHAT | Phathom Pharmaceuticals, Inc. |
VTYX | Ventyx Biosciences, Inc. |
CERE | Cerevel Therapeutics Holdings, Inc. |
COGT | Cogent Biosciences, Inc. |
SPRO | Spero Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
KRON | Kronos Bio, Inc. |
BOLT | Bolt Biotherapeutics, Inc. |
ACLX | Arcellx, Inc. |
GPCR | Structure Therapeutics Inc. |
NLTX | Neurogene Inc. |
KURA | Kura Oncology, Inc. |
CHRS | Coherus BioSciences, Inc. |
KRTX | Karuna Therapeutics, Inc. |
LYRA | Lyra Therapeutics, Inc. |
NVCT | Nuvectis Pharma, Inc. |